[HTML][HTML] Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review
MM Sampaio, MLC Santos, HS Marques… - World journal of …, 2021 - ncbi.nlm.nih.gov
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm and was the first
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …
Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map
RM Shallis, R Wang, A Davidoff, X Ma, NA Podoltsev… - Blood reviews, 2020 - Elsevier
The classical myeloproliferative neoplasms (MPNs), specifically chronic myeloid leukemia
(CML), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis …
(CML), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis …
Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells
Myeloproliferative neoplasms (MPNs) are blood cancers that are characterized by the
excessive production of mature myeloid cells and arise from the acquisition of somatic driver …
excessive production of mature myeloid cells and arise from the acquisition of somatic driver …
Identification of important genomic footprints using eight different selection signature statistics in domestic cattle breeds
In the present study, the population genomic data of different cattle breeds were explored to
decipher the genomic regions affected due to selective events and reflected in the …
decipher the genomic regions affected due to selective events and reflected in the …
Global, regional, and national burden of chronic myeloid leukemia, 1990–2017: a systematic analysis for the global burden of disease study 2017
Q Lin, L Mao, L Shao, L Zhu, Q Han, H Zhu, J Jin… - Frontiers in …, 2020 - frontiersin.org
Background With the advent of tyrosine kinase inhibitors (TKIs), the prognosis of chronic
myeloid leukemia (CML) seems to have dramatically improved over the last two decades …
myeloid leukemia (CML) seems to have dramatically improved over the last two decades …
[HTML][HTML] Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network …
Background Population-based information on cancer incidence, prevalence and outcome
are required to inform clinical practice and research; but contemporary data are lacking for …
are required to inform clinical practice and research; but contemporary data are lacking for …
Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia: Data from 151 patients
J Rohmer, A Couteau‐Chardon… - American Journal of …, 2020 - Wiley Online Library
Abstract FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia (F/P+ MN‐eo) is a
rare disease: robust epidemiological data are lacking and reported issues are scarce, of low …
rare disease: robust epidemiological data are lacking and reported issues are scarce, of low …
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation
Z Du, Z Huang, X Chen, G Jiang, Y Peng… - … Hematology & Oncology, 2022 - Springer
Background Tyrosine kinase inhibitors have achieved quite spectacular advances in the
treatment of chronic myeloid leukemia (CML), but disease progression and drug resistance …
treatment of chronic myeloid leukemia (CML), but disease progression and drug resistance …
Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study
L Ning, C Hu, P Lu, Y Que, X Zhu, D Li - Experimental hematology & …, 2020 - Springer
Background Outcomes of chronic myeloid leukemia (CML) has been improved dramatically
in the past two decades, but survival levels of CML patients varied in regions …
in the past two decades, but survival levels of CML patients varied in regions …
Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity
M Copland - British Journal of Haematology, 2022 - Wiley Online Library
Despite the success of BCR‐ABL‐specific tyrosine kinase inhibitors (TKIs) such as imatinib
in chronic phase (CP) chronic myeloid leukaemia (CML), patients with blast phase (BP) …
in chronic phase (CP) chronic myeloid leukaemia (CML), patients with blast phase (BP) …